Results from PLS-DA modeling.

<p>(A) Permutation test statistic at 2000 permutations with observed statistic of the model prediction accuracy with <i>p</i> < 0.0005. (B) VIP scores from the metabonomics model using two components. The boxes on the right represent the relative integral of the corresponding bin in each group (monoinfection and coinfection).</p

Results from PLS-DA modeling.

<p>(A) Permutation test statistic at 2000 permutations with observed statistic of the model prediction accuracy with <i>p</i> < 0.0005. (B) VIP scores from the metabonomics model using two components. The boxes on the right represent the relative integral of the corresponding bin in each group (monoinfection and coinfection).</p

Results from PLS-DA modeling.

<p>(A) Scores scatter plot discriminating among coinfected and monoinfected patients. (B) The optimal number of PLS-DA components, according to the squared correlation coefficient (R²), the predictive ability (Q²), and the accuracy of the model; the asterisk indicates the best number of components based on accuracy of the model.</p

¹H NMR spectra (PRESAT-CPMG, 300 MHz) of serum, with attribution of signals responsible for discrimination.

<p>¹H NMR spectra (PRESAT-CPMG, 300 MHz) of serum, with attribution of signals responsible for discrimination.</p

Clinical and laboratory characteristics of the coinfected (n = 18) and monoinfected groups (n = 22).

<p>Clinical and laboratory characteristics of the coinfected (n = 18) and monoinfected groups (n = 22).</p

Results from PCA modeling.

<p>(A) PCA scores of coinfected patients and monoinfected patients. (B) Loading scatter plot of PC1 versus PC2, explaining 80.7% of variance.</p